Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$862K Sell
30,714
-822
-3% -$21.9K 0.39% 36
2025
Q4
$785K Sell
31,536
-1,252
-4% -$31.6K 0.33% 35
2025
Q3
$835K Buy
32,788
+1,129
+4% +$27.9K 0.35% 34
2025
Q2
$767K Buy
31,659
+5,203
+20% +$121K 0.33% 35
2025
Q1
$669K Sell
26,456
-3,661
-12% -$95.8K 0.36% 34
2024
Q4
$799K Buy
30,117
+5,461
+22% +$148K 0.37% 34
2024
Q3
$714K Hold
24,656
0.36% 39
2024
Q2
$690K Sell
24,656
-83,472
-77% -$2.3M 0.36% 39
2024
Q1
$3M Buy
108,128
+249
+0.2% +$6.91K 1.24% 27
2023
Q4
$3.11M Buy
107,879
+47,358
+78% +$1.43M 1.11% 30
2023
Q3
$2.01M Sell
60,521
-35
-0.1% -$1.24K 0.91% 33
2023
Q2
$2.22M Sell
60,556
-39
-0.1% -$1.52K 0.95% 33
2023
Q1
$2.47M Sell
60,595
-384
-0.6% -$16.6K 1.15% 29
2022
Q4
$3.12M Buy
60,979
+31,933
+110% +$1.53M 1.52% 26
2022
Q3
$1.27M Sell
29,046
-8,239
-22% -$400K 0.64% 41
2022
Q2
$1.96M Buy
37,285
+3,192
+9% +$163K 0.84% 30
2022
Q1
$1.76M Sell
34,093
-3,002
-8% -$156K 0.62% 42
2021
Q4
$2.19M Buy
37,095
+12,278
+49% +$608K 0.65% 37
2021
Q3
$1.07M Buy
+24,817
New +$1.1M 0.41% 71

Other funds holding PFE

DCM Advisors's PFE Position: Q1 2026 in Review

DCM Advisors reduced its Pfizer (PFE) stake by 2.6% in Q1 2026, selling an estimated $21.9K and leaving 30,714 shares worth $862K. The position accounts for 0.39% of the portfolio, ranked #36.

DCM Advisors first reported a position in PFE in Q3 2021 and has held it in 19 quarters since. The position peaked at $3.12M in Q4 2022. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • DCM Advisors held 30,714 shares of Pfizer worth $862K as of Q1 2026.
  • DCM Advisors sold 822 Pfizer shares in Q1 2026, an estimated $21.9K.
  • Pfizer made up 0.39% of DCM Advisors's portfolio in Q1 2026, its #36 holding.
  • DCM Advisors first reported a position in Pfizer in Q3 2021 and has held it in 19 quarters since.
  • DCM Advisors's Pfizer position peaked at $3.12M in Q4 2022.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on DCM Advisors's 13F filing for Q1 2026, filed 15 May 2026.